Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 3/2013

01-06-2013 | Review Article

Diagnosis and Treatment of Pediatric Psoriasis: Current and Future

Author: Kara N. Shah

Published in: American Journal of Clinical Dermatology | Issue 3/2013

Login to get access

Abstract

Psoriasis is a common yet complex inflammatory dermatosis that may be seen in infants, children, and adolescents. The clinical presentation and course may be quite variable, and while patients with mild disease are often easily managed, those with recalcitrant or more severe disease often present a therapeutic dilemma given the number of therapies available and the relative lack of data on the efficacy and safety of use of these therapies in children. This review presents the reader with an overview of the current understanding of the pathophysiology, diagnosis, and treatment of pediatric psoriasis, with an emphasis on the available data in the literature that pertains to the use in children of currently available topical and systemic therapies, including topical corticosteroids, vitamin D analogs, phototherapy, systemic immunosuppressive medications, and biologic agents.
Literature
1.
Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermtol. 1985;13(3):450–6.CrossRef
2.
Fan X, Xiao FL, Yang S, et al. Childhood psoriasis: a study of 277 patients from China. JEADV. 2007;21(6):762–5.PubMed
3.
4.
Farber EM, Nall ML. Epidemiology: natural history and genetics. In: Roienigk HH, Maibach HI, editors. Psoriasis. 3rd ed. New York: Marcel Dekker; 1998. p. 107–58.
5.
Kumar B, Jain R, Sandhu K, et al. Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int J Dermatol. 2004;43(9):654–8.PubMedCrossRef
6.
Kwon HH, Na SJ, Jo SJ, et al. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol. 2012;39(3):260–4.PubMedCrossRef
7.
Tollefson MM, Crowson CS, McEvoy MT, et al. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979–87.PubMedCrossRef
8.
Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1–18.PubMedCrossRef
9.
Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17(3):174–8.PubMedCrossRef
10.
Neville EA, Finn OA. Psoriasiform napkin dermatitis: a follow-up study. Br J Dermatol. 1975;92(3):279–85.PubMedCrossRef
11.
Farber EM, Mullen RH, Jacobs AH, et al. Infantile psoriasis: a follow-up study. Pediatr Dermatol. 1986;3(3):237–43.PubMedCrossRef
12.
Boje Rasmussen H, Hagdrup H, Schmidt H. Psoriasiform napkin dermatitis. Acta Derm Venereol. 1986;66(6):534–6.PubMed
13.
Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23(5):437–43.PubMedCrossRef
14.
Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.PubMedCrossRef
15.
Ramsey SE, Bolaria RK, Cabral DA, et al. Comparison of criteria for the classification of childhood arthritis. J Rheumatol. 2000;27(5):1283–6.PubMed
16.
Stoll ML, Nigrovic PA, Gotte AC, et al. Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011;29(3):582–8.PubMed
17.
Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633–6.PubMedCrossRef
18.
Au SC, Goldminz AM, Loo DS, et al. Association between pediatric psoriasis and the metabolic syndrome. J Am Acad Dermatol. 2012;66(6):1012–3.PubMedCrossRef
19.
Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159(4):577–83.PubMedCrossRef
20.
Volf EM, Levine DE, Michelon MA, et al. Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts. J Drugs Dermatol. 2011;10(8):900–1.PubMed
21.
Zamberk P, Velazquez D, Campos M, et al. Paediatric psoriasis: narrowband UVB treatment. JEADV. 2010;24(4):415–9.PubMed
22.
Bilgic A, Bilgic O, Akis HK, et al. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Derm. 2010;27(6):614–7.CrossRef
23.
Varni JW, Globe DR, Gandra SR, et al. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr. 2012;171(3):485–92.PubMedCrossRef
24.
Michalak-Stoma A, Pietrzak A, Szepietowski JC, et al. Cytokine network in psoriasis revisited. Eur Cytokine Netw. 2011;22(4):160–8.PubMed
25.
Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827–51.PubMedCrossRef
26.
Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol. 2000;143(6):1177–82.PubMedCrossRef
27.
Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90(5):784–95.PubMedCrossRef
28.
Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. New Engl J Med. 2011;365(7):620–8.PubMedCrossRef
29.
Rahman P, Elder JT. Genetics of psoriasis and psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39(2):431–3.PubMedCrossRef
30.
Chandran V. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;14(2):149–56.CrossRef
31.
Ozden MG, Tekin NS, Gurer MA, et al. Environmental risk factors in pediatric psoriasis: a multicenter case-control study. Pediatr Dermatol. 2011;28(3):306–12.PubMedCrossRef
32.
Rasmussen JE. The relationship between infection with group A beta hemolytic streptococci and the development of psoriasis. Pediatr Infect Dis J. 2000;19(2):153–4.PubMed
33.
Leung DY, Travers JB, Giorno R, et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest. 1995;96(5):2106–12.PubMedCrossRef
34.
Honig PJ. Guttate psoriasis associated with perianal streptococcal disease. J Pediatr. 1988;113(6):1037–9.PubMedCrossRef
35.
Owen CM, Chalmers RJ, O’Sullivan T, et al. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev. 2000;2:CD001976.PubMed
36.
Eberhard BA, Sundel RP, Newburger JW, et al. Psoriatic eruption in Kawasaki disease. J Pediatr. 2000;137(4):578–80.PubMedCrossRef
37.
Han MH, Jang KA, Sung KJ, et al. A case of guttate psoriasis following Kawasaki disease. Br J Dermatol. 2000;142(3):548–50.PubMedCrossRef
38.
Kishimoto S, Muneuchi J, Takahashi Y, et al. Psoriasiform skin lesion and supprative acrodermatitis associated with Kawasaki disease followed by the treatment with infliximab: a case report. Acta Paediatr. 2010;99(7):1102–4.PubMedCrossRef
39.
Liao YC, Lee JY. Psoriasis in a 3-month-old infant with Kawasaki disease. Dermatol Online J. 2009;15(11):10.PubMed
40.
Ergin S, Karaduman A, Demirkaya E, et al. Plaque psoriasis induced after Kawasaki disease. Turk J Pediatr. 2009;51(4):375–7.PubMed
41.
Yoon SY, Oh ST, Lee JY, et al. Plaque type psoriasiform eruption following Kawasaki disease. Pediatr Dermatol. 2007;24(3):336–7.PubMedCrossRef
42.
Yoon SY, Oh ST, Lee JY, et al. A plaque type psoriasiform eruption following Kawasaki disease. Pediatr Dermatol. 2007;24(1):96–8.PubMedCrossRef
43.
Mizuno Y, Suga Y, Muramatsu S, et al. Psoriasiform and palmoplanter pustular lesions induced after Kawasaki disease. Int J Dermatol. 2006;45(9):1080–2.PubMedCrossRef
44.
Menni S, Gualandri L, Boccardi D, et al. Association of psoriasis-like eruption and Kawasaki disease. J Dermatol. 2006;33(8):571–3.PubMedCrossRef
45.
Tsai HJ, Wu WM, Chang YC, et al. Annular pustules in Kawasaki disease: a further case indicating the association with psoriasis? Cutis. 2003;72(5):354–6.PubMed
46.
Zvulunov A, Greenberg D, Cagnano E, et al. Development of psoriatic lesions during acute and convalescent phases of Kawasaki disease. J Paediatr Child Health. 2003;39(3):229–31.PubMedCrossRef
47.
Garty B, Mosseri R, Finkelstein Y. Guttate psoriasis following Kawasaki disease. Pediatr Dermatol. 2001;18(6):507–8.PubMedCrossRef
48.
49.
Howard R, Tsuchiya A. Adult skin disease in the pediatric patient. Dermatol Clin. 1998;16(3):593–608.PubMedCrossRef
50.
Morris A, Rogers M, Fischer G, et al. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol. 2001;18(3):188–98.PubMedCrossRef
51.
Nanda A, Kaur S, Kaur I, et al. Childhood psoriasis: an epidemiologic survey of 112 patients. Pediatr Dermatol. 1990;7(1):19–21.PubMedCrossRef
52.
al-Fouzan AS, Nanda A. A survey of childhood psoriasis in Kuwait. Pediatr Dermatol. 1994;11(2):116–9.PubMedCrossRef
53.
Hutton KP, Orenberg EK, Jacobs AH. Childhood psoriasis. Cutis. 1987;39(1):26–7.PubMed
54.
Rasmussen JE. Psoriasis in children. Dermatol Clin. 1986;4(1):99–106.PubMed
55.
Nyfors A, Lemholt K. Psoriasis in children: a short review and a survey of 245 cases. Br J Dermatol. 1975;92(4):437–42.PubMedCrossRef
56.
Herbst RA, Hoch O, Kapp A, et al. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol. 2000;42(5 Pt 2):885–7.PubMedCrossRef
57.
Nyfors A. Psoriasis in children: characteristics, prognosis and therapy: a review. Acta Derm Venereol Suppl (Stockh). 1981;95:47–53.
58.
Tervaert WC, Esseveld H. A study of the incidence of haemolytic streptococci in the throat in patients with psoriasis vulgaris, with reference to their role in the pathogenesis of this disease. Dermatologica. 1970;140(5):282–90.PubMedCrossRef
59.
Whyte HJ, Baughman RD. Acute guttate psoriasis and streptococcal infection. Arch Dermatol. 1964;89:350–6.PubMedCrossRef
60.
Telfer NR, Chalmers RJ, Whale K, et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;128(1):39–42.PubMedCrossRef
61.
62.
63.
64.
Lever WF, Elder DE. Lever’s histopathology of the skin. 10th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009.
65.
Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25(6):524–8.PubMedCrossRef
66.
Vogel SA, Yentzer B, Davis SA, et al. Trends in pediatric psoriasis outpatient health care delivery in the United States. Arch Dermatol. 2012;148(1):66–71.PubMedCrossRef
67.
Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17(5):364–75.PubMedCrossRef
68.
Bhutani T, Kamangar F, Cordoro KM. Management of pediatric psoriasis. Pediatr Ann. 2012;41(1):e1–7.PubMed
69.
de Jager ME, de Jong EM, van de Kerkhof PC, et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62(6):1013–30.PubMedCrossRef
70.
Lara-Corrales I, Xi N, Pope E. Childhood psoriasis treatment: evidence published over the last 5 years. Rev Recent Clin Trials. 2011;6(1):36–43.PubMedCrossRef
71.
Gelmetti C. Therapeutic moisturizers as adjuvant therapy for psoriasis patients. Am J Clin Dermatol. 2009;10(Suppl. 1):7–12.PubMedCrossRef
72.
Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991;25(6 Pt 2):1166–9.PubMedCrossRef
73.
Kimball AB, Gold MH, Zib B, et al. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol. 2008;59(3):448–54, 454.e1.
74.
Ahn SJ, Oh SH, Chang SE, et al. A case of infantile psoriasis with pseudoainhum successfully treated with topical pimecrolimus and low-dose narrowband UVB phototherapy. JEADV. 2006;20(10):1332–4.PubMed
75.
Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. JEADV. 2004;18(6):742–3.PubMed
76.
Mansouri P, Farshi S. Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J. 2006;12(2):7.PubMed
77.
Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24(1):76–80.PubMedCrossRef
78.
Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol. 2005;53(4):713–6.PubMedCrossRef
79.
Choi YJ, Hann SK, Chang SN, et al. Infantile psoriasis: successful treatment with topical calcipotriol. Pediatr Dermatol. 2000;17(3):242–4.PubMedCrossRef
80.
Darley CR, Cunliffe WJ, Green CM, et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135(3):390–3.PubMedCrossRef
81.
Oranje AP, Marcoux D, Svensson A, et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol. 1997;36(2 Pt 1):203–8.PubMedCrossRef
82.
Park SB, Suh DH, Youn JI. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol. 1999;16(4):321–5.PubMedCrossRef
83.
Patrizi A, Neri I, Rizzoli L, et al. Topical calcipotriol in childhood psoriasis. Acta Derm Venereol. 1999;79(6):477.PubMedCrossRef
84.
Perez A, Chen TC, Turner A, et al. Pilot study of topical calcitriol (1,25-dihydroxyvitamin D3) for treating psoriasis in children. Arch Dermatol. 1995;131(8):961–2.PubMedCrossRef
85.
Saggese G, Federico G, Battini R. Topical application of 1,25-dihydroxyvitamin D3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children. Eur J Pediatr. 1993;152(5):389–92.PubMedCrossRef
86.
Travis LB, Silverberg NB. Psoriasis in infancy: therapy with calcipotriene ointment. Cutis. 2001;68(5):341–4.PubMed
87.
Comaish JS. Tar and related compounds in the therapy of psoriasis. Clin Exp Dermatol. 1981;6(6):639–45.PubMedCrossRef
88.
89.
Borska L, Fiala Z, Krejsek J, et al. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2007;24(6):607–12.PubMedCrossRef
90.
Kortuem KR, Davis MD, Witman PM, et al. Results of Goeckerman treatment for psoriasis in children: a 21-year retrospective review. Pediatr Dermatol. 2010;27(5):518–24.PubMedCrossRef
91.
Menter MA, Whiting DA, McWilliams J. Resistant childhood psoriasis: an analysis of patients seen in a day-care center. Pediatr Dermatol. 1984;2(1):8–12.PubMedCrossRef
92.
Borska L, Andrys C, Krejsek J, et al. Genotoxic hazard and cellular stress in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2009;26(1):23–7.PubMedCrossRef
93.
Diluvio L, Campione E, Paterno EJ, et al. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%. Pediatr Dermatol. 2007;24(3):332–3.PubMedCrossRef
94.
Zvulunov A, Anisfeld A, Metzker A. Efficacy of short-contact therapy with dithranol in childhood psoriasis. Int J Dermatol. 1994;33(11):808–10.PubMedCrossRef
95.
Guerrier CJ, Porter DI. An open assessment of 0.1% dithranol in a 17% urea base (‘Psoradrate’ 0.1%) in the treatment of psoriasis of children. Curr Med Res Opin. 1983;8(6):446–50.PubMedCrossRef
96.
Pavlovsky M, Baum S, Shpiro D, et al. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? JEADV. 2011;25(6):727–9.PubMed
97.
98.
Pasic A, Ceovic R, Lipozencic J, et al. Phototherapy in pediatric patients. Pediatr Dermatol. 2003;20(1):71–7.PubMedCrossRef
99.
Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol. 1996;13(5):406–9.PubMedCrossRef
100.
Jain VK, Aggarwal K, Jain K, et al. Narrow-band UV-B phototherapy in childhood psoriasis. Int J Dermatol. 2007;46(3):320–2.PubMedCrossRef
101.
Pahlajani N, Katz BJ, Lozano AM, et al. Comparison of the efficacy and safety of the 308 nm excimer laser for the treatment of localized psoriasis in adults and in children: a pilot study. Pediatr Dermatol. 2005;22(2):161–5.PubMedCrossRef
102.
Gelfand JM, Wan J, Callis Duffin K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148(4):487–94.PubMedCrossRef
103.
Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001–17.PubMedCrossRef
104.
Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(4):1263–71.PubMedCrossRef
105.
Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–88.PubMedCrossRef
106.
Kopp T, Karlhofer F, Szepfalusi Z, et al. Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol. 2004;151(4):912–6.PubMedCrossRef
107.
de Oliveira ST, Maragno L, Arnone M, et al. Generalized pustular psoriasis in childhood. Pediatr Dermatol. 2010;27(4):349–54.PubMedCrossRef
108.
Xiao T, Li B, He CD, et al. Juvenile generalized pustular psoriasis. J Dermatol. 2007;34(8):573–6.PubMedCrossRef
109.
Juanqin G, Zhiqiang C, Zijia H. Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases. Pediatr Dermatol. 1998;15(2):144–6.PubMedCrossRef
110.
Chao PH, Cheng YW, Chung MY. Generalized pustular psoriasis in a 6-week-old infant. Pediatr Dermatol. 2009;26(3):352–4.PubMedCrossRef
111.
Salleras M, Sanchez-Regana M, Umbert P. Congenital erythrodermic psoriasis: case report and literature review. Pediatr Dermatol. 1995;12(3):231–4.PubMedCrossRef
112.
Judge MR, McDonald A, Black MM. Pustular psoriasis in childhood. Clin Exp Dermatol. 1993;18(2):97–9.PubMedCrossRef
113.
Ergin S, Ersoy-Evans S, Sahin S, et al. Acitretin is a safe treatment option for infantile pustular psoriasis. J Dermatol Treat. 2008;19(6):341–3.CrossRef
114.
Rosinska D, Wolska H, Jablonska S, et al. Etretinate in severe psoriasis of children. Pediatr Dermatol. 1988;5(4):266–72.PubMedCrossRef
115.
Karamfilov T, Wollina U. Juvenile generalized pustular psoriasis. Acta Derm Venereol. 1998;78(3):220.PubMedCrossRef
116.
Shelnitz LS, Esterly NB, Honig PJ. Etretinate therapy for generalized pustular psoriasis in children. Arch Dermatol. 1987;123(2):230–3.PubMedCrossRef
117.
Liao PB, Rubinson R, Howard R, et al. Annular pustular psoriasis: most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol. 2002;19(1):19–25.PubMedCrossRef
118.
Al-Shobaili H, Al-Khenaizan S. Childhood generalized pustular psoriasis: successful treatment with isotretinoin. Pediatr Dermatol. 2007;24(5):563–4.PubMedCrossRef
119.
Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60(5):824–37.PubMedCrossRef
120.
Kumar B, Dhar S, Handa S, et al. Methotrexate in childhood psoriasis. Pediatr Dermatol. 1994;11(3):271–3.PubMedCrossRef
121.
Dogra S, Handa S, Kanwar AJ. Methotrexate in severe childhood psoriasis. Pediatr Dermatol. 2004;21(3):283–4.PubMedCrossRef
122.
Dogra S, Kumaran MS, Handa S, et al. Methotrexate for generalized pustular psoriasis in a 2-year-old child. Pediatr Dermatol. 2005;22(1):85–6.PubMedCrossRef
123.
124.
Kaur I, Dogra S, De D, et al. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol. 2008;25(2):184–8.PubMedCrossRef
125.
Garg T, Chander R, Mittal S. Familial juvenile generalized pustular psoriasis: response to methotrexate. Skinmed. 2011;9(3):190–1.PubMed
126.
Collin B, Vani A, Ogboli M, et al. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol. 2009;34(3):295–8.PubMedCrossRef
127.
Scott RB, Surana R. Erythrodermic psoriasis in childhood: a young Negro child treated with methotrexate. Am J Dis Child. 1968;116(2):218–21.PubMed
128.
Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655–62.PubMedCrossRef
129.
Pereira TM, Vieira AP, Fernandes JC, et al. Cyclosporin A treatment in severe childhood psoriasis. JEADV. 2006;20(6):651–6.PubMed
130.
Perrett CM, Ilchyshyn A, Berth-Jones J. Cyclosporin in childhood psoriasis. J Dermatol Treat. 2003;14(2):113–8.
131.
Kilic SS, Hacimustafaoglu M, Celebi S, et al. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001;18(3):246–8.PubMedCrossRef
132.
Alli N, Gungor E, Karakayali G, et al. The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol. 1998;139(4):754–5.PubMedCrossRef
133.
Kim HS, Kim GM, Kim SY. Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy. Pediatr Dermatol. 2006;23(3):306–8.PubMedCrossRef
134.
Nakamura S, Hashimoto Y, Igawa S, et al. Childhood generalized pustular psoriasis treated by preprandial ciclosporin administration: serum cytokine pattern during the course of the disease. Clin Exp Dermatol. 2009;34(8):e1023–4.PubMedCrossRef
135.
Mahe E, Bodemer C, Pruszkowski A, et al. Cyclosporine in childhood psoriasis. Arch Dermatol. 2001;137(11):1532–3.PubMed
136.
Marji JS, Marcus R, Moennich J, et al. Use of biologic agents in pediatric psoriasis. J Drugs Dermatol. 2010;9(8):975–86.PubMed
137.
Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol. 2010;6(10):561–71.PubMedCrossRef
138.
Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–50.PubMedCrossRef
139.
Pontikaki I, Shahi E, Frasin LA, et al. Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2012;42(2):131–4.PubMedCrossRef
140.
Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742–51.PubMedCrossRef
141.
Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861–72.PubMedCrossRef
142.
Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144(2):200–7.PubMedCrossRef
143.
Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(2):304–14.PubMedCrossRef
144.
Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):661–8.PubMedCrossRef
145.
Gottlieb AB, Leonardi C, Kerdel F, et al. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):652–60.PubMedCrossRef
146.
Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol. 2011;12(2):113–25.PubMedCrossRef
147.
Hawrot AC, Metry DW, Theos AJ, et al. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol. 2006;23(1):67–71.PubMedCrossRef
148.
Kress DW. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl. 2):S126–8.PubMedCrossRef
149.
Papoutsaki M, Costanzo A, Mazzotta A, et al. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006;154(1):181–3.PubMedCrossRef
150.
Safa G, Loppin M, Bousser AM, et al. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis. J Am Acad Dermatol. 2007;56(2 Suppl.):S19–20.PubMedCrossRef
151.
Fabrizi G, Guerriero C, Pagliarello C. Etanercept in infants: suberythrodermic, recalcitrant psoriasis in a 22 month-old child successfully treated with etanercept. Eur J Dermatol. 2007;17(3):245.PubMed
152.
Floristan U, Feltes R, Ramirez P, et al. Recalcitrant palmoplantar pustular psoriasis treated with etanercept. Pediatr Dermatol. 2011;28(3):349–50.PubMedCrossRef
153.
Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology. 2006;213(4):350–2.PubMedCrossRef
154.
Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. New Engl J Med. 2008;358(3):241–51.PubMedCrossRef
155.
Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63(5):762–8.PubMedCrossRef
156.
Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatol Treat. 2005;16(5–6):350–2.CrossRef
157.
Alvarez AC, Rodriguez-Nevado I, De Argila D, et al. Recalcitrant pustular psoriasis successfully treated with adalimumab. Pediatr Dermatol. 2011;28(2):195–7.PubMedCrossRef
158.
Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 2004;21(1):87–8.PubMedCrossRef
159.
Farnsworth NN, George SJ, Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J. 2005;11(3):11.PubMed
160.
Rott S, Kuster RM, Mrowietz U. Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko. Br J Dermatol. 2007;157(1):191–2.PubMedCrossRef
161.
Perman MJ, Lovell DJ, Denson LA, et al. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol. 2012;29(4):454–9.PubMedCrossRef
162.
Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52(2):230–2.PubMedCrossRef
163.
Pourciau C, Shwayder T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr Dermatol. 2010;27(5):539–40.PubMedCrossRef
164.
Stuart P, Malick F, Nair RP, et al. Analysis of phenotypic variation in psoriasis as a function of age at onset and family history. Arch Dermatol Res. 2002;294(5):207–13.PubMed
165.
Ferrandiz C, Pujol RM, Garcia-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002;46(6):867–73.PubMedCrossRef
Metadata
Title
Diagnosis and Treatment of Pediatric Psoriasis: Current and Future
Author
Kara N. Shah
Publication date
01-06-2013
Publisher
Springer International Publishing AG
Published in
American Journal of Clinical Dermatology / Issue 3/2013
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-013-0026-8

Other articles of this Issue 3/2013

American Journal of Clinical Dermatology 3/2013 Go to the issue

Original Research Article

Pulsed Dye Laser in the Treatment of Localized Scleroderma and Its Effects on CD34+ and Factor XIIIa+ Cells: An Immunohistochemical Study

Review Article

Penicillamine Revisited: Historic Overview and Review of the Clinical Uses and Cutaneous Adverse Effects

Evidence-Based Review Article

The Effect of Folate Supplementation on Methotrexate Efficacy and Toxicity in Psoriasis Patients and Folic Acid Use by Dermatologists in the USA

Review Article

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions

Review Article

Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice

Review Article

Etiology and Therapeutic Management of Erythema Nodosum During Pregnancy: An Update